When patients take HIV medication, a small amount of the virus nonetheless stays hidden in the body, preventing a cure. This hiding place has finally been uncovered in a groundbreaking study led by UZ Gent researchers. With this ‘viral reservoir’ identified, researchers may finally be able to develop a cure for this devastating disease.
The first edition of Science for health was held in the heart of Brussels on 11th September 2019 with a focus on cell therapy. The event attracted over 300 researchers, clinicians and industry professionals active in the the local or international cell therapy ecosystem. Top-speakers provided interesting insights into the current state of cell therapy in Belgium, as well as requirements for further progress. Collaboration, especially outside of the traditional partnerships, is key.
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a closer look at the agreement. Why is this deal so unique in the biotech world? What will the ripple effects be in the European ecosystem? BioVox spoke with Lenny Van Steenhuyse, Healthcare Equity Analyst at KBC Securities, for a deeper insight.
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. Networking opportunities, like the annual Knowledge for Growth event and Science for health, stimulate research collaboration by connecting people. So, what’s the role of a cluster organization in all this? BioVox spoke with flanders.bio representatives Pascale Engelen and Katrien Lorré to find out.
The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case.
When patients take HIV medication, a small amount of the virus nonetheless stays hidden in the body, preventing a cure. This hiding place has finally been uncovered in a groundbreaking study led by UZ Gent researchers. With this ‘viral reservoir’ identified, researchers may finally be able to develop a cure for this devastating disease.
The first edition of Science for health was held in the heart of Brussels on 11th September 2019 with a focus on cell therapy. The event attracted over 300 researchers, clinicians and industry professionals active in the the local or international cell therapy ecosystem. Top-speakers provided interesting insights into the current state of cell therapy in Belgium, as well as requirements for further progress. Collaboration, especially outside of the traditional partnerships, is key.
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a closer look at the agreement. Why is this deal so unique in the biotech world? What will the ripple effects be in the European ecosystem? BioVox spoke with Lenny Van Steenhuyse, Healthcare Equity Analyst at KBC Securities, for a deeper insight.
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. Networking opportunities, like the annual Knowledge for Growth event and Science for health, stimulate research collaboration by connecting people. So, what’s the role of a cluster organization in all this? BioVox spoke with flanders.bio representatives Pascale Engelen and Katrien Lorré to find out.
The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case.